{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:22:47Z","timestamp":1793604167024,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"30","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000046","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000046","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Research Council"},{"DOI":"10.13039\/100004807","name":"DFG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry of Education and Research"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bertelsmann Foundation and Heinz-Nixdorf Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) with the Amplatzer\u2122 Amulet\u2122 occluder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with atrial fibrillation eligible for LAAO were recruited to a prospective global study. Implant procedures were undertaken with echocardiographic guidance. Transoesophageal echocardiography (TOE) was undertaken 1\u20133 months post-LAAO. Implant and follow-up TOEs were evaluated by a CoreLab. The primary endpoint was a composite of ischaemic stroke and cardiovascular death at 2 years. Serious adverse events were adjudicated by an independent clinical events committee. A total of 1088 patients were enrolled, aged 75.2\u2009\u00b1\u20098.5 years; 64.5% were male. CHA2DS2-VASc and HAS-BLED scores were 4.2\u2009\u00b1\u20091.6 and 3.3\u2009\u00b1\u20091.1, respectively. A total of 71.7% had prior major bleeding, and 82.8% had contraindications to oral anticoagulants. Implant success was 99.1%. Major adverse events (\u22647 days post-procedure) occurred in 4.0%, including death (0.3%), stroke (0.4%), major vascular (1.3%), and device embolization (0.2%). A total of 80.2% of patients were discharged on antiplatelet therapy alone. Peridevice flow was &amp;lt;3\u2009mm in 98.4% at follow-up TOE. Device-related thrombus (DRT) was seen in 1.6% of cases. Cardiovascular death or ischaemic stroke occurred in 8.7% of patients at 2 years. The ischaemic stroke rate was 2.2%\/year\u2014a 67% reduction compared to the CHA2DS2-VASc predicted rate. Major bleeding (Bleeding Academic Research Consortium type\u2009\u2265\u20093) occurred at rates of 10.1%\/year (year 1) and 4.0%\/year (year 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Following LAAO with the Amplatzer Amulet device, the ischaemic stroke rate was reduced by 67% compared to the predicted risk. Closure was complete in 98.4% of cases and DRT seen in only 1.6%.<\/jats:p>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaa169","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T15:15:52Z","timestamp":1582730152000},"page":"2894-2901","source":"Crossref","is-referenced-by-count":164,"title":["Left atrial appendage occlusion with the Amplatzer\u2122 Amulet\u2122 device: full results of the prospective global observational study"],"prefix":"10.1093","volume":"41","author":[{"given":"David","family":"Hildick-Smith","sequence":"first","affiliation":[{"name":"Department of Cardiology, Sussex Cardiac Centre, Brighton and Sussex University Hospitals , 177 Preston Rd, Brighton BN1 6AGE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin , Charit\u00e9pl. 1, Berlin 10117, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A John","family":"Camm","sequence":"additional","affiliation":[{"name":"Cardiology Clinical Academic Group Molecular & Clinical Sciences Institute, St. George\u2019s University of London , Cranmer Terrace, Tooting, London SW17 0RE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, , Hufelandstra\u00dfe 55, Essen 45147, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , 11 Robin Warren Dr 6150, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Cardioangiologisches Centrum Bethanien, Wilhelm-Epstein-Stra\u00dfe 4 , Frankfurt 60431, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7731-6730","authenticated-orcid":false,"given":"Magnus","family":"Settergren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Karolinska Universitetssjukhuset, Eugeniav\u00e4gen 3 , Solna 171 76, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-4344","authenticated-orcid":false,"given":"Emmanuel","family":"Teiger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Henri Mondor, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny , 94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Erik","family":"Nielsen-Kudsk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus N, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tondo","sequence":"additional","affiliation":[{"name":"Heart Rhythm Centre at Monzino Cardiac Center, IRCCS, Department of Clinical Sciences and Community Health, University of Milan , Via Francesco Sforza 35, Milan 20122, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"2022102507122159300_ehaa169-B1","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102507122159300_ehaa169-B2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102507122159300_ehaa169-B3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ijcard.2012.12.093","article-title":"Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century","volume":"167","author":"Ball","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022102507122159300_ehaa169-B4","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"2022102507122159300_ehaa169-B5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102507122159300_ehaa169-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022102507122159300_ehaa169-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102507122159300_ehaa169-B8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"2022102507122159300_ehaa169-B9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"key":"2022102507122159300_ehaa169-B10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4244\/EIJY15M01_06","article-title":"Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug","volume":"11","author":"Tzikas","year":"2016","journal-title":"EuroIntervention"},{"key":"2022102507122159300_ehaa169-B11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4244\/EIJ-D-17-00493","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical\/echocardiographic data from a global prospective observational study","volume":"13","author":"Landmesser","year":"2017","journal-title":"EuroIntervention"},{"key":"2022102507122159300_ehaa169-B12","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.4244\/EIJ-D-18-00344","article-title":"Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry","volume":"14","author":"Landmesser","year":"2018","journal-title":"EuroIntervention"},{"key":"2022102507122159300_ehaa169-B13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"2022102507122159300_ehaa169-B14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022102507122159300_ehaa169-B15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jcin.2019.02.003","article-title":"Incidence, characterization, and clinical impact of device-related thrombus following left atrial appendage occlusion in the prospective global AMPLATZER Amulet Observational Study","volume":"12","author":"Aminian","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102507122159300_ehaa169-B16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4244\/EIJ-D-16-00726","article-title":"Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy","volume":"12","author":"Korsholm","year":"2017","journal-title":"EuroIntervention"},{"key":"2022102507122159300_ehaa169-B17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijcard.2017.07.052","article-title":"Left atrial appendage closure using AMPLATZER devices: a large, multicenter, Italian registry","volume":"248","author":"Berti","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022102507122159300_ehaa169-B18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"key":"2022102507122159300_ehaa169-B19","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/eurheartj\/eht174","article-title":"Atrial fibrillation and the \u2018other drug problem\u2019: reducing non-adherence with technology","volume":"34","author":"Nerini","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102507122159300_ehaa169-B20","first-page":"449","article-title":"Long-term event reduction after left atrial appendage closure. Results of the Iberian Registry II","volume":"72","author":"Lopez-Minguez","year":"2019","journal-title":"Rev Esp Cardiol (Engl Ed)"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/30\/2894\/46616750\/eurheartj_41_30_2894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/30\/2894\/46616750\/eurheartj_41_30_2894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T03:12:51Z","timestamp":1666667571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/30\/2894\/5815608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":20,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020,4,3]]},"published-print":{"date-parts":[[2020,8,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa169","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,7]]},"published":{"date-parts":[[2020,4,3]]}}}